Parkinson's disease and cardiovascular involvement: Edifying insights (Review)

Biomed Rep. 2023 Feb 14;18(3):25. doi: 10.3892/br.2023.1607. eCollection 2023 Mar.

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative illnesses, and is a major healthcare burden with prodigious consequences on life-quality, morbidity, and survival. Cardiovascular diseases are the leading cause of mortality worldwide and growing evidence frequently reports their co-existence with PD. Cardiac dysautonomia due to autonomic nervous system malfunction is the most prevalent type of cardiovascular manifestation in these patients, comprising orthostatic and postprandial hypotension, along with supine and postural hypertension. Moreover, many studies have endorsed the risk of patients with PD to develop ischemic heart disease, heart failure and even arrhythmias, but the underlying mechanisms are not entirely clear. As importantly, the medication used in treating PD, such as levodopa, dopamine agonists or anticholinergic agents, is also responsible for cardiovascular adverse reactions, but further studies are required to elucidate the underlying mechanisms. The purpose of this review was to provide a comprehensive overview of current available data regarding the overlapping cardiovascular disease in patients with PD.

Keywords: Parkinson's disease; cardiac dysautonomia; cardiovascular disease; heart disease; heart failure; levodopa.

Publication types

  • Review

Grants and funding

Funding: No funding was received.